Bioreactors

Donaldson acquires Isolere Bio

21-Feb-2023 By Rachel Arthur

Donaldson Company will acquire Isolere Bio: an early-stage biotech that develops novel and proprietary ‘IsoTag’ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

CBM looks to boost viral vector manufacturing capabilities in cell line deal

19-Jan-2023 By Jane Byrne

The unprecedented rise in approvals for new cell and gene therapies, and the increasing industry need for cell lines to support the production of therapeutics, has spurred US CDMO, the Center for Breakthrough Medicines (CBM), to act

BioNTech acquires GMP manufacturing site in Singapore

14-Nov-2022 By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

Lonza: N-1 perfusion capability enables increased process titers

04-Nov-2022 By Jane Byrne

The biopharma sector has seen recent advancements in process intensification, especially in relation to upstream processing, with the technology employed aimed at increasing drug output. One of the quickest and simplest ways to achieve process intensification...

ReiThera opens new viral vector production manufacturing facility

03-Nov-2022 By Rachel Arthur

ReiThera has received operational authorization from the Italian Medicines Agency (AIFA) to open a new production area at its facility near Rome for the large-scale production of viral vectors for vaccines and gene therapy.

RoosterBio and MBL Beijing Biotech team up to accelerate advanced therapy manufacturing in China

01-Sep-2022 By Rachel Arthur

RoosterBio has entered into an exclusive distributor partnership with MBL Beijing Biotech: with RoosterBio’s expansion media, exosome collection media, bioreactor media and genetic engineering media to be sold and distributed by MBL Beijing and thus becoming...

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Fujifilm to invest $1.6bn and make its Hillerød facility in Denmark the largest end-to-end CDMO in Europe

30-Jun-2022 By Jane Byrne

Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).

Umoja and TreeFrog team up to overcome challenges facing ex vivo allogeneic therapies

14-Jun-2022 By Jane Byrne

Umoja Biopharma and TreeFrog Therapeutics have formed an alliance to address challenges facing ex vivo allogeneic therapies in immuno-oncology, including issues scaling up production to reach all patients.

Evotec expands cell therapy manufacturing with acquisition

31-May-2022 By Ben Hargreaves

Evotec agrees to acquire Rigenerand, which adds a manufacturing facility capable of producing cell therapies to its infrastructure in Italy.

AGC Biologics adds new viral vector suspension capabilities at US cell & gene facility

19-May-2022 By Rachel Arthur

AGC Biologics will add viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Colorado.

Catalent to invest $350m to expand US drug substance and product manufacturing site

22-Apr-2022 By Jane Byrne

Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.

Asahi Kasei Medical acquires US biologics CDMO business

21-Apr-2022 By Jane Byrne

Bionova Scientific, a US biologics CDMO, is to be acquired by the US arm of Asahi Kasei Medical, part of the Asahi Kasei Group, owned by Tokyo based Asahi Kasei Corporation.

Catalent buys UK vaccine manufacturing centre

07-Apr-2022 By Rachel Arthur

US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

Abzena secures $65m to expand production capacity, mammalian biologics site set to come online

31-Mar-2022 By Jane Byrne

Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.

From textiles to therapies: North Carolina’s journey to a booming biotech hub

29-Mar-2022 By Rachel Arthur

While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...

Vaccine and gene therapy focused CDMO secures GMP certification for Belgian site

25-Mar-2022 By Jane Byrne

Exothera, a CDMO specializing in the industrialization of vaccine and gene therapy processes, reports that it has achieved GMP certification for its facilities in Jumet, Belgium.

Catalent completes $30m expansion to biologics network

22-Mar-2022 By Ben Hargreaves

Catalent completes expansion of its biologics manufacturing network by upgrading its Limoges, France, location with additional capacity and the ability to produce large molecules.

WHO establishes global biomanufacturing training hub in Korea

25-Feb-2022 By Rachel Arthur

A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.

Wageningen University, VectorY team up to develop next gen AAV expression systems

26-Jan-2022 By Jane Byrne

Netherlands-based gene therapy company, VectorY Therapeutics, and Wageningen University have signed a strategic collaboration agreement for the development of novel baculovirus-based AAV production technologies.

Fujifilm Diosynth in $300m expansion of largest single-use facility in North America

20-Dec-2021 By Ben Hargreaves

The investment comes as part of a wider $850m global expansion by parent company Fujifilm Corporation of its biologics CDMO subsidiary.

Donaldson Company strengthens presence in biopharma with Solaris Biotechnology acquisition

23-Nov-2021 By Rachel Arthur

Donaldson Company, Inc., a global provider of filtration products and solutions, has acquired Solaris Biotechnology Srl for around €41m ($46m).

Culture riding virtual R&D wave, latest funding round enables development of cloud bioreactors

12-Nov-2021 By Jane Byrne

Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, recently announced an $80m Series B round, taking the funds it has raised to date to $100m+.

Fujifilm Diosynth in tie-up with US AAV gene therapy developer

14-Oct-2021 By Jane Byrne

LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.

Thermo Fisher opens Swiss biologics production facility

04-Oct-2021 By Jane Byrne

The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.

Thermo Fisher Scientific to double SUT manufacturing capacity with new Nashville site

09-Sep-2021 By Rachel Arthur

Thermo Fisher Scientific Inc. will create a manufacturing facility in Nashville dedicated to the production of single-use technologies (SUT) products.

Rentschler Biopharma to use Industry 4.0 to transform manufacturing at new Boston site

18-Aug-2021 By Jane Byrne

Earlier this month, Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced that it had broken ground on its new production facility, adjacent to its existing site in Milford, Massachusetts, in the greater Boston...

Special Edition: Meeting demand for viral vectors

VIVEbiotech looks to overcome challenges related to LVV production

18-Aug-2021 By Jane Byrne

VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....

WTO lists critical inputs for COVID-19 vaccines to address gaps in global supply

05-Aug-2021 By Nick Taylor

The World Trade Organization (WTO) Secretariat has published a list of critical inputs for COVID-19 vaccines as part of an effort to address gaps in global production and distribution of the products.

Spotlight on single-use systems: 3 trends driving demand

03-Aug-2021 By Staff reporter

Adoption of single-use technologies has grown exponentially over the last decade: but what will drive the tech forward in the coming years?

Sartorius downplays threat of Chinese regulatory changes to single-use tech

02-Aug-2021 By Nick Taylor

Sartorius has expressed confidence that demand for single-use technologies will be unaffected by changes to the regulation of biologics in China.

Cytiva and Pall to spend $1.5bn on manufacturing capacity expansion, new hires

27-Jul-2021 By Jane Byrne

Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally

Generate looks to in-house stem cell manufacturing

22-Jul-2021 By Jane Byrne

Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.

Pall inks $7m deal with Exothera for suspension based production of viral vectors

19-Jul-2021 By Jane Byrne

Filtration, separation and purification specialist, Pall, has announced a new contract valued at over US$7M with full-service CDMO, Exothera.

Univercells Technologies in tie-up with Chinese player on viral vectors for CGT and vaccine sectors

12-Jul-2021 By Jane Byrne

Belgium’s Univercells Technologies and China’s VectorBuilder have entered a strategic global partnership for custom viral vector production.

Fujifilm continues to expand its biologics CDMO business, ploughing further $850m into US and UK sites

08-Jul-2021 By Jane Byrne

Fujifilm Corporation has made an additional US$850m investment to enable the expansion of its BIO-CMDO sites in the UK, at Billingham, and in the US.

Algenex receives EMA validation for insect-based manufacturing platform

25-Jun-2021 By Ben Hargreaves

Algenex takes step towards commercialization of insect platform with recommendation for approval to manufacture vaccines.

Lonza to provide manufacturing for ValenzaBio from China facility

23-Jun-2021 By Ben Hargreaves

Lonza will provide drug substance and product manufacturing for the biotech’s anti-IGF-1R antibody.

KBI Biopharma enters commercial manufacturing deal with AM-Pharma

22-Jun-2021 By Ben Hargreaves

The manufacturing agreement concerns AM-Pharma’s recAP program, a potential treatment for kidney disease.

Univercells and NIBRT partnership looks to plug gaps in CGT manufacturing skillset

25-May-2021 By Jane Byrne

Univercells Technologies’ scale-x carbo bioreactor is to be used at the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland.

'Connectivity is a key enabler for continuous manufacturing'

12-May-2021 By Jane Byrne

Connectivity of unit operations is a key enabler for continuous manufacturing to deliver benefits of not only improved mass throughput, but ultimately reduced COGS and increased facility utilization, says Merck.

Catalent looks to meet needs of expanding CGT market, completes expansion work at biologics drug substance facility

27-Apr-2021 By Jane Byrne

Contract development and manufacturing organization, Catalent, has invested in the capabilities at its clinical supply services facility in Philadelphia, in the US, to further support biotech firms developing cell and gene therapies.

Plant-derived COVID-19 vaccine candidate starts rolling review with Health Canada

27-Apr-2021 By Rachel Arthur

Medicago has started a rolling submission with Health Canada for its plant-derived adjuvanted COVID-19 vaccine candidate: championing a unique and versatile platform that can also be scaled up easily.

From biosimilars to process intensification: 5 key trends in the biopharma space today

20-Apr-2021 By Jane Byrne

Efficiency in the biopharmaceutical space has never been more top-of-mind. The COVID-19 pandemic brought an unprecedented urgency to R&D and the key players delivered: Several groups produced a vaccine in record time. To maintain and improve on this...

Abzena choses North Carolina for new $200m biologics manufacturing site

15-Apr-2021 By Rachel Arthur

Global Partner Research Organization Abzena will build a new GMP manufacturing facility in Sanford, North Carolina.

COVID-19 vaccine manufacturing centre gains MHRA approval; ready to produce tens of millions of doses in the UK

06-Oct-2020 By Rachel Arthur

The UK’s Vaccines Manufacturing & Innovation Centre (VMIC) announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the second of two GMP COVID-19 vaccine manufacturing suites located at Oxford Biomedica's...

Serum Institute to double COVID-19 vaccine productivity with ABEC’s bioreactors

30-Sep-2020 By Rachel Arthur

The Serum Institute of India will receive six 4,000L CSR bioreactors from ABEC to help it scale up manufacture of Novavax’s COVID-19 vaccine candidate.

‘Viral vector production demand will ultimately exceed the current global capacity’

23-Sep-2020 By Jane Byrne

Catalent recently announced that it is investing US$130m in an expansion project at its viral vector manufacturing facility located in Harmans, Maryland, with five new manufacturing suites set to respond to a growing customer pipeline and market demand.

Using HSV helper viruses to increase AAV production

23-Sep-2020 By Nick Taylor

Recognizing the industry-wide need to improve adeno-associated virus (AAV) vector manufacturing, Applied Genetic Technologies Corporation (AGTC) has adopted changes intended to increase yield and purity.